Brooklyn ImmunoTherapeutics’ $125 Million Acquisition of Novellus

Philip Lee advised Novellus on the deal.Brooklyn ImmunoTherapeutics has completed its acquisition of engineered cellular medicine company Novellus Therapeutics Limited. This acquisition advances Brooklyn’s evolution into…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here
Federica Tiefenthaler

Author: Federica Tiefenthaler

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

Brooklyn ImmunoTherapeutics’ $125 Million Acquisition of Novellus

Philip Lee advised Novellus on the deal.Brooklyn ImmunoTherapeutics has completed its acquisition of engineered cellular medicine company Novellus Therapeutics Limited. This acquisition advances Brooklyn’s evolution into…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here
Federica Tiefenthaler

Author: Federica Tiefenthaler

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here